The studies analyzed several genetic disorders, primarily NF1, examined in 77.8% of the studies (Arnold et al., 2021; Chaix et al., 2018; Descheemaeker et al., 2005; Hou et al., 2023; Hyman et al., 2006; Janke et al., 2014; Siegel et al., 2024), DS (11.1%) (Kirk et al., 2017) and FXS (11.1%) (Jordan et al., 2023). This evidence concerns the gene NF1 and Dravet syndrome.